BioSyent Inc. (CVE:RX - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$10.89 and traded as high as C$11.15. BioSyent shares last traded at C$11.05, with a volume of 8,284 shares changing hands.
BioSyent Stock Performance
The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. The firm has a market capitalization of C$127.49 million, a price-to-earnings ratio of 18.33 and a beta of 0.93. The firm has a 50 day moving average price of C$11.32 and a 200-day moving average price of C$10.90.
Insider Transactions at BioSyent
In related news, Senior Officer Robert Joseph March sold 4,775 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Also, insider FAX Capital Corp. sold 230,800 shares of the stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00. Insiders have sold 349,144 shares of company stock valued at $3,903,370 in the last quarter. 33.65% of the stock is currently owned by corporate insiders.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
See Also
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
